Stiff Man Syndrome This variant is sometimes called the Jerking Stiff Person syndromeor Progressive Encephalomyelitis with rigidity. Investigations. http://www.in-hln.org.uk/stiffman.htm
On Target - Weekly Journal, Issue January 13, 2002 HISTORY OF MEDICINE The Hospital Ship III. IMMUNOLOGY Stiff Person syndrome(SPS) IV. III. IMMUNOLOGY back to top. Stiff Person syndrome (SPS). http://www.targethealth.com/01132002.htm
Extractions: TARGET HEALTH I. WHAT'S NEW back to top American Society of Clinical Pharmacology and Therapeutics Annual Meeting TARGET HEALTH is pleased to announce that our good friend and colleague Dr. Otto Mills (UMDNJ), will chair the Dermatology Session Symposium at the annual meeting of the ASCPT in Atlanta this March. Dr. Jonathan Wilkin (FDA) will also be presenting at the symposium, entitled Streamlining the Path to the Market. Dr. Mitchels presentation will address the use of Internet-based clinical trials. TARGET HEALTH will also be presenting a poster at the meeting.
ADVANCE For Audiologists | Daily News Watch An immunologic therapy administered to patients with stiff person syndrome (SPS)provides dramatic relief from disabling symptoms, according to a new study ( A http://www.advanceforaud.com/previousdnw/aadnw0121.html
Extractions: DAILY NEWS WATCH Updated Daily, Monday through Friday January 25, 2002 Immunotherapy Has Dramatic Results for Neurological Disorder An immunologic therapy administered to patients with stiff person syndrome (SPS) provides dramatic relief from disabling symptoms, according to a new study ("A Randomized Controlled Trial of High-Dose Intravenous Immunoglobulin in the Treatment of Patients with Stiff Person Syndrome," by M. Dalakas, M. Fujii, M Li, et al., New England Journal of Medicine , 345: 1870-1876). The therapy is intravenous immunoglobulin (IVIg). The success of the treatment supports the theory that SPS is the result of an autoimmune response gone awry in the brain and spinal cord, stated principal author Marinos C. Dalakas, MD, chief of the Neuromuscular Diseases Section of the National Institute of Neurological Disorders and Stroke (NINDS). SPS is characterized by fluctuating muscle rigidity in the trunk and limbs and a heightened sensitivity to stimuli such as noise, touch and emotional distress that can set off muscular spasms. People with SPS often are too disabled to walk or move or are afraid to leave their house because of stimuli-triggered spasms and frequent falls. Since the 1980s, researchers have known that people with SPS have elevated circulating antibodies against a particular enzyme, glutamic acid decarboxylase (GAD65). This enzyme is involved in the synthesis of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that controls muscle movement. Since GABA modulates the action of the excitatory muscular neurotransmitters, lower levels of circulating GABA allow the excitatory neurotransmitters to hijack communications between the brain and the motor system, overstimulating the muscles into stiffness and spasm.
Extractions: Previous Story ... Related Stories Next Story Source: NIH/National Institute On Aging Date: An immunologic therapy, intravenous immunoglobulin (IVIg), administered to patients suffering from stiff person syndrome (SPS), provides dramatic relief from disabling symptoms, according to a study appearing in the December 27, 2001, issue of The New England Journal of Medicine.* The studys principal author, Marinos C. Dalakas, M.D., chief of the Neuromuscular Diseases Section of the National Institute of Neurological Disorders and Stroke, says that the success of the treatment supports the theory that SPS is the result of an autoimmune response gone awry in the brain and spinal cord. SPS is characterized by fluctuating muscle rigidity in the trunk and limbs and a heightened sensitivity to stimuli such as noise, touch, and emotional distress that can set off muscular spasms. People with SPS are often too disabled to walk or move, or are afraid to leave the house because of stimuli-triggered spasms and frequent falls. The incidence of SPS has been estimated at one in every one million persons, but according to Dr. Dalakas, the disorder is so often misdiagnosed as Parkinsons disease, multiple sclerosis, fibromyalgia, psychosomatic illness, or anxiety and phobia that its actual incidence is probably much higher.
Médecine Interne Translate this page Commentaire au 26-05-00. Commentaires (Dr. P.Blanche) - Le syndrome de l'hommeraide (STIFF man syndrome ou mieux STIFF person syndrome ou encore mieux http://www.uvp5.univ-paris5.fr/UV_MED/MINT/STAF/Staff152.ASP
Extractions: Patient de 71 ans, hospitalisé pour douleurs musculaires et articulaires avec altération de l'état général. Antécédents Histoire de la maladie - Mars Cliniquement Examens complémentaires Syndrome inflammatoire discret VS : 24, CRP à 25. Bilan hépatique, T4, TSH, aldolase, EPS, Ca Ph, LDH et CPK, C3C4, glycémie à jeûn normale. Anticorps anti-centromère et anti-nucléaires négatifs. Sérologies coxsakie, CMV, toxoplasmose, Lyme négatives.
Itb-candidate/selection Criteria Stroke, Cerebral Hemmorhage, Traumatic Brain Injury, Cerebral Palsy, AnoxicEncephalopathy, Stiff Person syndrome, Encephalitis, Near Drowning. http://www.southshoreneurologic.com/clinical/itb/itb-candidate.html
Katalog - Wirtualna Polska Serwis Katalog w Wirtualna Polska S.A. pierwszy portal w Polsce. http://katalog.wp.pl/DMOZ/Health/Conditions_and_Diseases/Neurological_Disorders/
Welcome To The Pain Management Center Ice packs cold packs. MRI. Pic shoulder tear. RSDS. St. John's Wort. Stiff-personsyndrome. The Active Release Technique - ART. Pain Mgmt. Center Links http://www.citihealth.com/layout.Cfm?HC=25&Body=CenterArticle
Extractions: Received: 16 May 2002 / Accepted in revised form: 10 July 2002 Abstract. Glutamic acid decarboxylase (GAD) is the enzyme that catalyses the production of GABA, a major neurotransmitter of the central nervous system. Antibodies to GAD (GAD-Ab) were first recognised in a patient affected by stiff-person syndrome; subsequently they were reported in a large number of cases with type 1 diabetes. Recently GADAb have been described in a number of patients affected by chronic cerebellar ataxia, drug-resistant epilepsy and myoclonus. These cases usually harbour other autoantibodies or are affected by organ-specific autoimmune diseases. The role of GAD-Ab is still unclear; the lack of experimental models makes it difficult to investigate their potential pathogenetic role. However two mechanisms have been suggested: the reduction by GAD-Ab of GABA synthesis in nerve terminals or the interference with exocytosis of GABA. Key words Article in PDF format (62 KB) Online publication: January 16, 2003